Engineer, Genetic Engineering and Immune Response

Rubius Therapeutics Presents Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, Demonstrating its Dual Mechanism of Action

BioTech 365

OCTOBER 28, 2020

RTX-321 Induces Antigen-Specific Stimulation Combined with Broad Stimulation of Innate and Adaptive Immune Responses CAMBRIDGE, Mass., Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an … Continue reading →

Genetic Engineering

Genetic Engineering Immune Response Engineer Genetics

COVID prompts another milestone, as India clears first DNA vaccine

pharmaphorum

AUGUST 23, 2021

DNA vaccines work by delivering a genetically-engineered plasmid containing the DNA sequence encoding the desired antigen – in this case the SARS-CoV-2 spike protein – which is then taken up by cells. Proponents of the approach claim that DNA vaccines may have advantages over other technologies like mRNA.

DNA

DNA Vaccination Vaccine Genetic Engineering

ESMO: TIL therapy improves on Yervoy in melanoma trial

pharmaphorum

SEPTEMBER 11, 2022

The patient then receives chemotherapy to reduce regulatory T cells that can put a brake on immune responses to tumours, as well as immune-boosting cytokine interleukin-2, before the TILs are then reinfused into the patient intravenously.

Trials

Trials Genetic Engineering Immune Response Engineer

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

AstraZeneca-Oxford COVID-19 Vaccine Shows High Efficacy

XTalks

NOVEMBER 23, 2020

Oxford-AstraZeneca COVID-19 Vaccine Induces Immune Responses in Early Clinical Trials. The global trials are assessing the safety and efficacy of the vaccine in individuals aged 18 years or over from diverse racial and geographic groups who are healthy or have stable underlying medical conditions.

Vaccination

Vaccination Vaccine Clinical Trials Clinical Trials

Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 VaccineAdvance purchase agreement signed for NVX-CoV2373, Novavax’ adjuvanted protein vaccine candidate

The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. About Novavax. Novavax, Inc.?(Nasdaq: Novavax Forward Looking Statements.

Protein

Protein Vaccination Vaccine Immune Response

Taconic Biosciences Expands Immuno-oncology Animal Model PortfolioCritical Jh Syngeneic Tumor Model Host Now Available on a B6 Background

The Pharma Data

JANUARY 17, 2021

These models are engrafted with mouse tumors derived from the same strain background; this genetic similarity between tumor and host prevents the host from rejecting the tumor. One consideration in using syngeneic models is that some drug candidates can cause a negative immune response not seen in humans.

Genetic Engineering

Genetic Engineering Genetics Engineer Immune Response

The New Frontier in Drug Development: Understanding Biologics and Small Molecules

Cloudbyz

MARCH 5, 2024

They are often used to mimic or enhance natural biological processes, such as immune responses. Immunogenicity : Small Molecules: Generally have a lower risk of inducing an immune response in the body. Biologics: Biologics can work in a variety of ways, including targeting specific cells, proteins, or pathways.

Development

Development Drugs Immune Response Manufacturing

In the precision medicine era, the line between products and services is blurred

pharmaphorum

SEPTEMBER 4, 2020

The treatments are developed using cutting- edge technologies such as genomic sequencing and genetic engineering, helping to account for the individual variability in both patient and disease characteristics. CAR-T is a new individualized cancer immunotherapy that has taken precision medicine to a new level.

Medicine

Medicine Production Genetic Engineering Genetics

Blocking enzyme could hold the key to preventing, treating severe COVID-19

The Pharma Data

JUNE 1, 2022

Blocking an immune response-related enzyme holds promise in preventing or treating severe COVID-19 symptoms by reducing inflammation, tissue injury and blood clots in the lungs, new research in mice suggests. Previous research has shown that caspase 11 in mice has many of the same immune-response functions as caspase 4 in humans.

Immune Response

Immune Response Genetic Engineering Research Engineer

Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA

The Pharma Data

NOVEMBER 9, 2020

NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.?Novavax?is

Vaccination

Vaccination Vaccine Clinical Trials Clinical Trials

Novavax Announces COVID-19 Vaccine Clinical Development Progress

The Pharma Data

NOVEMBER 30, 2020

About NVX-CoV2373 NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.?Novavax?is

Clinical Development

Clinical Development Vaccination Vaccine Development

Using bispecific antibodies to advance cancer immunotherapy

pharmaphorum

NOVEMBER 2, 2021

The more targeted, bispecific functionality of bsAbs broadens the reach of antibody-mediated therapies against both solid and haematological cancers, creating novel approaches that can induce a tumour-specific immune response, target immune checkpoints, or improve payload delivery to tumour cells (Fig.

Antibody

Antibody Immune Response Production Engineer

Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease in PREVENT-19 Phase 3 trial

The Pharma Data

JUNE 25, 2021

NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. Department of Health and Human Services (HHS), and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) at HHS.

Vaccination

Vaccination Vaccine Trials Immune Response

mRNA Cancer Vaccines and Therapies: An Overview

Advarra

JANUARY 11, 2024

After injection of such a vaccine, the mRNA instructs cells to produce proteins designed to stimulate an immune response against these same protein targets when they show up in viruses or in tumor cells. Adoptive T Cell Therapies Adoptive T cell therapy is another form of cancer treatment leveraging the patient’s immune system.

Vaccination

Vaccination Vaccine Protein Antibody

A broad range of unmet needs remains in the immuno-oncology space

Pharmaceutical Technology

MAY 2, 2023

The most widely utilised IO class is immune checkpoint inhibitors (ICIs), which work by blocking the inhibitory interactions between tumour cells and T-cells, facilitating an anti-tumour immune response. There are more than 20 marketed ICIs with approvals across a very wide spectrum of solid tumour indications.

Genetic Engineering

Genetic Engineering Antibody Clinical Trials Clinical Trials

Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform

XTalks

AUGUST 17, 2020

Cue Biopharma is a Cambridge, Massachusetts-based clinical-stage biotechnology company that is focused on developing injectable immune biologics using its proprietary Immuno-STAT (Selective Targeting and Alteration of T cells) platform. Cell-Based Immunotherapy vs. Immune Biologics. Immune system modulators (i.e.

Protein

Protein Engineer Immune Response In-Vivo

Pfizer/BioNTech COVID jab works against Brazil variant; lab study

pharmaphorum

MARCH 10, 2021

The study suggests that serum taken from patients injected with the mRNA shot, also known as BNT162b2, was able to neutralise a genetically engineered version of SARS-CoV-2 with the P.1 1 – that is worrying health officials around the world. . 1 mutations, as well as variants from the UK and South Africa.

Vaccination

Vaccination Vaccine Genetic Engineering Engineer

South African variant may cut response from Pfizer/BioNTech shot, study finds

pharmaphorum

FEBRUARY 18, 2021

Researchers from the University of Texas Medical Branch based their findings on lab tests using SARS-CoV-2 coronaviruses that were genetically engineered to have the same mutations as those in the strain that is causing scientists so much concern.

Immune Response

Immune Response Genetic Engineering Vaccination Vaccine

Spotlighting Lupus Awareness Month: CAR-T Technology Creates New Avenues for Treatment of a Devastating Disease

WCG Clinical

MAY 28, 2024

CAR-T Cells Target Harmful B Cells in Lupus CAR-T cell technology, which uses genetic engineering to direct white blood cells to attack specific molecular targets, was originally proposed for treatment of HIV infection and hematological malignancies.

In-Vivo

In-Vivo Clinical Trials Clinical Trials FDA Approval

Biopharma Leaders Unite To Stand With Science

The Pharma Data

SEPTEMBER 8, 2020

Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies.

Vaccination

Vaccination Vaccine Containment Clinical Trials

Biopharma Leaders Unite To Stand With Science

The Pharma Data

SEPTEMBER 8, 2020

Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies.

Vaccination

Vaccination Vaccine Containment Clinical Trials

Clinical Research Informer

Rubius Therapeutics Presents Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, Demonstrating its Dual Mechanism of Action

COVID prompts another milestone, as India clears first DNA vaccine

Webinars

Trending Sources

ESMO: TIL therapy improves on Yervoy in melanoma trial

Webinars

AstraZeneca-Oxford COVID-19 Vaccine Shows High Efficacy

Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 VaccineAdvance purchase agreement signed for NVX-CoV2373, Novavax’ adjuvanted protein vaccine candidate

Taconic Biosciences Expands Immuno-oncology Animal Model PortfolioCritical Jh Syngeneic Tumor Model Host Now Available on a B6 Background

The New Frontier in Drug Development: Understanding Biologics and Small Molecules

In the precision medicine era, the line between products and services is blurred

Blocking enzyme could hold the key to preventing, treating severe COVID-19

Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA

Novavax Announces COVID-19 Vaccine Clinical Development Progress

Using bispecific antibodies to advance cancer immunotherapy

Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease in PREVENT-19 Phase 3 trial

mRNA Cancer Vaccines and Therapies: An Overview

A broad range of unmet needs remains in the immuno-oncology space

Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform

Pfizer/BioNTech COVID jab works against Brazil variant; lab study

South African variant may cut response from Pfizer/BioNTech shot, study finds

Spotlighting Lupus Awareness Month: CAR-T Technology Creates New Avenues for Treatment of a Devastating Disease

Biopharma Leaders Unite To Stand With Science

Biopharma Leaders Unite To Stand With Science

Stay Connected